Mercator Medical S.A. (FRA:MM2)
Germany · Delayed Price · Currency is EUR 9.53
-0.03 (-0.31%)
At close: Jan 30, 2026
Mercator Medical Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 585.36 | 542.49 | 469.06 | 542.51 | 1,727 | 1,834 |
Other Revenue | 0.21 | 0.21 | 0.16 | 0.25 | 1.86 | 1.21 |
| 585.57 | 542.69 | 469.23 | 542.77 | 1,729 | 1,835 | |
Revenue Growth (YoY) | 14.77% | 15.66% | -13.55% | -68.61% | -5.79% | 240.06% |
Cost of Revenue | 423.97 | 401.58 | 366.4 | 445.94 | 1,084 | 645.87 |
Gross Profit | 161.59 | 141.11 | 102.83 | 96.82 | 644.96 | 1,190 |
Selling, General & Admin | 140.8 | 132.78 | 135.84 | 144.94 | 147.73 | 116.92 |
Other Operating Expenses | 10.73 | 8.53 | 18.39 | 0.97 | 14.96 | 6.91 |
Operating Expenses | 178.8 | 164.61 | 176.35 | 171.57 | 182 | 142.35 |
Operating Income | -17.2 | -23.5 | -73.52 | -74.75 | 462.96 | 1,047 |
Interest Expense | -0.44 | -0.33 | -0.83 | -0.33 | -0.12 | -3.95 |
Interest & Investment Income | 16.29 | 21.44 | 23.68 | 14.06 | 0.84 | 0.74 |
Earnings From Equity Investments | -0.02 | - | - | - | 2.28 | - |
Currency Exchange Gain (Loss) | 12.49 | -13 | 40.09 | -17.22 | 19.02 | -2.9 |
Other Non Operating Income (Expenses) | 8.6 | 0.44 | 8.05 | 24.21 | -1.12 | 1.04 |
EBT Excluding Unusual Items | 19.71 | -14.95 | -2.53 | -54.03 | 483.86 | 1,042 |
Gain (Loss) on Sale of Investments | 1.88 | 3.12 | 14.53 | -4.93 | -6.38 | -0.13 |
Gain (Loss) on Sale of Assets | -1.59 | -1.65 | -0.37 | 0.47 | 0.1 | -1.26 |
Asset Writedown | 56.26 | 55.54 | -15.3 | -127.52 | - | - |
Legal Settlements | -0.32 | -0.2 | -0.12 | -0.21 | -0.35 | -0.14 |
Pretax Income | 75.96 | 41.86 | -3.79 | -186.22 | 477.23 | 1,041 |
Income Tax Expense | -21.97 | -7.97 | 19.04 | 4.57 | 32.37 | 105 |
Earnings From Continuing Operations | 97.93 | 49.83 | -22.84 | -190.79 | 444.85 | 935.57 |
Minority Interest in Earnings | -0.17 | 1.22 | 3.16 | 1.16 | 2.01 | -5.38 |
Net Income | 97.76 | 51.05 | -19.68 | -189.62 | 446.87 | 930.19 |
Net Income to Common | 97.76 | 51.05 | -19.68 | -189.62 | 446.87 | 930.19 |
Net Income Growth | - | - | - | - | -51.96% | - |
Shares Outstanding (Basic) | 9 | 9 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 9 | 9 | 10 | 10 | 10 | 11 |
Shares Change (YoY) | -1.96% | -2.02% | -1.91% | -3.47% | -3.88% | -0.55% |
EPS (Basic) | 10.56 | 5.44 | -2.05 | -19.41 | 44.15 | 88.66 |
EPS (Diluted) | 10.56 | 5.44 | -2.05 | -19.41 | 44.15 | 88.33 |
EPS Growth | - | - | - | - | -50.02% | - |
Free Cash Flow | -99.91 | -90.78 | -39.15 | -68.86 | 326.25 | 696.97 |
Free Cash Flow Per Share | -10.79 | -9.67 | -4.08 | -7.05 | 32.23 | 66.19 |
Dividend Per Share | 1.610 | 1.610 | - | - | - | - |
Gross Margin | 27.60% | 26.00% | 21.91% | 17.84% | 37.30% | 64.81% |
Operating Margin | -2.94% | -4.33% | -15.67% | -13.77% | 26.77% | 57.05% |
Profit Margin | 16.69% | 9.41% | -4.19% | -34.94% | 25.84% | 50.68% |
Free Cash Flow Margin | -17.06% | -16.73% | -8.34% | -12.69% | 18.87% | 37.97% |
EBITDA | 5.32 | -4.71 | -53.87 | -50.74 | 481.34 | 1,065 |
EBITDA Margin | 0.91% | -0.87% | -11.48% | -9.35% | 27.84% | 58.02% |
D&A For EBITDA | 22.52 | 18.79 | 19.66 | 24.01 | 18.38 | 17.79 |
EBIT | -17.2 | -23.5 | -73.52 | -74.75 | 462.96 | 1,047 |
EBIT Margin | -2.94% | -4.33% | -15.67% | -13.77% | 26.77% | 57.05% |
Effective Tax Rate | - | - | - | - | 6.78% | 10.09% |
Revenue as Reported | 649.84 | 613.75 | 514.69 | 605.48 | 1,733 | 1,839 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.